FDA Simultaneously Approves Roche/Plexxikon's Drug, Companion Dx for BRAF-Mutated Melanoma
August 17, 2011
FDA Simultaneously Approves Roche/Plexxikon's Drug, Companion Dx for BRAF-Mutated Melanoma
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- PGx Highlights from the American Society of Clinical Oncology's 2012 Meeting
June 14, 2012 / Pharmacogenomics Reporter - UK's NICE Cites Lack of Response Markers for BMS' Yervoy as Factor in Negative Recommendation
October 19, 2011 / Pharmacogenomics Reporter - Plexxikon, Roche File Rx/Dx Application for PLX4032, Cobas Mutation Test in Metastatic Melanoma
May 18, 2011 / Pharmacogenomics Reporter - During Investor Day, Roche Highlights Personalized Medicine as Key Area for Future Growth
September 12, 2012 / Pharmacogenomics Reporter - Roche Says FDA-Approved BRAF Test Is Better Than Sanger-based LDTs, but is it Enough to Sway Labs?
September 28, 2011 / Pharmacogenomics Reporter